Youcare Pharmaceutical (SH:688658) Xin Lang Cai Jing·2026-01-09 05:59Group 1 - The core viewpoint of the news is that Yuyuan Pharmaceutical has seen a significant increase in stock price and trading volume, indicating positive market sentiment towards the company [1] - As of January 9, Yuyuan Pharmaceutical's stock price rose by 5.2% to 28.55 CNY per share, with a trading volume of 204 million CNY and a turnover rate of 1.65%, resulting in a total market capitalization of 12.847 billion CNY [1] - The company, established in August 2001 and listed in December 2020, focuses on the research and production of high-end chemical drugs, with major revenue contributions from cardiovascular, digestive, diabetes, and anti-infection medications [1] Group 2 - Yuyuan Pharmaceutical's main products include Ginkgo biloba extract injection, Tianma extract injection, Lansoprazole injection, Omeprazole enteric-coated capsules, Metformin sustained-release tablets, Cefuroxime sodium injection, and Ceftriaxone sodium injection, which are expected to have significant revenue contributions and growth potential [1] - The revenue composition of Yuyuan Pharmaceutical is as follows: cardiovascular drugs 55.67%, anti-infection drugs 20.88%, raw materials 8.73%, digestive system drugs 6.87%, diabetes drugs 4.85%, and others 2.62% [1] Group 3 - Red Tower Hongtu Fund has a significant holding in Yuyuan Pharmaceutical, with its Red Tower Hongtu Medical Selected Stock Fund A (020331) holding 23,000 shares, accounting for 3.82% of the fund's net value, ranking as the tenth largest holding [2] - The fund has achieved a year-to-date return of 3.15%, ranking 2758 out of 5509 in its category, and a one-year return of 37.37%, ranking 2023 out of 4198 [2]